Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 3OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 90Breast Neoplasms 87Melanoma 86Multiple Myeloma 69Carcinoma, Non-Small-Cell Lung 63Leukemia, Myeloid, Acute 62Lymphoma 59Brain Neoplasms 57Glioblastoma 55Ovarian Neoplasms 51Neoplasms 51Carcinoma, Renal Cell 49Lymphoma, Non-Hodgkin 47Fallopian Tube Neoplasms 47Leukemia, Lymphocytic, Chronic, B-Cell 45Sarcoma 44Gliosarcoma 43Neoplasm Metastasis 39Lung Neoplasms 36Carcinoma, Hepatocellular 35Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Pancreatic Neoplasms 33Glioma 33Lymphoma, Large B-Cell, Diffuse 32Uterine Cervical Neoplasms 31Hematologic Neoplasms 31Colonic Neoplasms 31Small Cell Lung Carcinoma 29Myelodysplastic Syndromes 28Rhabdomyosarcoma 27

Interventions

Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Has results × Anal Canal Carcinoma × Clear all
NCT02314169 2026-05-28

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
143 enrolled 16 charts
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡